QIAGEN reports results for Q1 2024 ahead of outlook, on track to achieve full-year 2024 guidanceGlobeNewsWire • 04/29/24
QIAGEN expands tuberculosis portfolio with new NGS Panel to support real-time surveillance and combat antimicrobial resistanceGlobeNewsWire • 04/24/24
Unveiling Qiagen (QGEN) Q1 Outlook: Wall Street Estimates for Key MetricsZacks Investment Research • 04/24/24
QIAGEN strengthens its portfolio for cancer research, showcasing latest product launches at AACR Annual Meeting 2024GlobeNewsWire • 04/03/24
QIAGEN introduces QIAstat-Dx Analyzer 2.0 with remote test results access, enhancing collaboration across healthcare systemGlobeNewsWire • 03/25/24
QIAGEN partners with International Panel Physicians Association to increase awareness of tuberculosis screening requirementsGlobeNewsWire • 03/18/24
Qiagen (QGEN) Up 1.1% Since Last Earnings Report: Can It Continue?Zacks Investment Research • 03/07/24
QIAGEN launches AI-derived biomedical knowledge base to accelerate data-driven drug discoveryGlobeNewsWire • 02/27/24
QIAGEN earns ACT Label for new eco-friendlier QIAwave products and achieves first My Green Lab Platinum certificationGlobeNewsWire • 02/27/24
QIAGEN exceeds outlook for Q4 2023, led by 8% CER sales growth in non-COVID products and improved operational profitabilityGlobeNewsWire • 02/06/24
QIAGEN announces partnership with Penn State University to advance microbiome sciencesGlobeNewsWire • 01/25/24
QIAGEN announces details for completion of synthetic share repurchase of up to approximately $300 millionGlobeNewsWire • 01/18/24